If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Hologic (HOLX) . This company, which is in the Zacks Medical - Instruments industry, shows potential for another earnings beat.When looking at the last two reports, this medical device maker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 3.93%, on average, in the last two qua ...

股价表现 - Hologic (HOLX) 最近的股价为 $76.35，较前一天收盘价上涨了 +0.58% [1] - Hologic 的股价在过去一个月上涨了 2.87%，超过了医疗行业的增长率和标普500指数的增长率 [2] 财务表现 - Hologic 即将发布的财报备受投资者关注，预计每股收益为 $0.98，同比下降了 7.55% [3] - 分析师预计全年Hologic的每股收益为 $4.02，营收为 $4.02 亿美元，较去年分别增长了 +1.52% 和 -0.19% [5] 估值和行业排名 - Hologic 的估值方面，目前的前瞻市盈率为 18.9，低于行业平均值 27.51 [9] - HOLX 的 PEG 比率为 2.57，高于医疗仪器行业的平均 PEG 比率 2.24 [10] - 医疗仪器行业属于医疗领域，目前的 Zacks 行业排名为 54，在所有 250+ 个行业中处于前 22% [11]

公司业绩 - Hologic在过去四个季度均超出盈利预测，每次也超出营收预测[13] - 公司上一季度营收和EPS较去年同期有所下降，但超出Zacks Consensus Estimate[11] - 分析师对Hologic的盈利预测变化与股价走势有强相关性，当前季度和未来几年的盈利预测均有变化[4] 估值评级 - Hologic的估值评级为B，表明其相对同行业处于折价状态[17] 市场表现 - Hologic是一家医疗器械制造商，股票表现略逊于Zacks S&P 500综合指数和医疗器械行业，关键问题是股票未来走势[2] Zacks评级 - Hologic的Zacks Rank评级为3 (Hold)，基于盈利预测变化等因素[8] 投资决策 - 公司的估值对于投资决策至关重要，需要考虑当前股价是否反映了公司的内在价值和增长前景[14] 总结展望 - 总结显示，虽然市场对Hologic的关注度可能有所影响，但Zacks Rank 3暗示其未来表现可能与整体市场持平[18]

In the latest market close, Hologic (HOLX) reached $75.64, with a -0.9% movement compared to the previous day. This change lagged the S&P 500's daily gain of 1.12%. Meanwhile, the Dow experienced a rise of 0.61%, and the technology-dominated Nasdaq saw an increase of 1.54%.Prior to today's trading, shares of the medical device maker had gained 3.07% over the past month. This has outpaced the Medical sector's gain of 2.49% and the S&P 500's gain of 2.06% in that time.The investment community will be paying c ...

Hologic, Inc. (HOLX) and its subsidiary, Biotheranostics, recently presented new research findings. The results suggest that in the absence of Breast Cancer Index (BCI) genetic testing, a significant proportion of early-stage hormone receptor-positive (HR+) breast cancer survivors may have received excessive or insufficient treatment. The study was published in the March issue of the JNCCN — Journal of the National Comprehensive Cancer Network.Previous research has shown that most women with early-stage HR+ ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced newly published study results revealing that use of the Breast Cancer Index® (BCI) test led to physicians changing their long-term anti-estrogen treatment recommendations for 40% of patients with early-stage hormone receptor-positive (HR+) breast cancer.1 The results, which suggest that many women may be over- or undertreated without the incorporation of BCI, reflect real-world data f ...

Hologic (HOLX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this medical device maker have returned +1.7%, compared to the Zacks S&P 500 composite's +4.8% change. During this period, the Zacks Medical - Instruments industry, which Hologic falls in, has gained 4.7%. The key question now is: What could be the stock's future direction?Although media repor ...

mapodile/E+ via Getty Images Shares of Hologic (NASDAQ:HOLX) have been trading relatively stagnant in recent years, while the underlying business has seen quite some volatility since the outset of the pandemic. This creates quite an interesting set-up. While lucrative pandemic-related sales are on their retreat, Hologic has seen continued growth, bought back shares and maintained balance sheet discipline. All this has gradually pushed down valuations to quite appealing multiples, amidst solid organic growth ...

Hologic和SONOVA HOLDING - Hologic和SONOVA HOLDING是医疗仪器股票中备受投资者关注的公司[1] - Hologic的Zacks Rank为2（买入），而SONOVA HOLDING的Zacks Rank为3（持有）[2] 估值和盈利预期 - HOLX的估值指标和盈利预期表现均优于SONVY[8] - HOLX在价值投资者眼中更具吸引力[8]

Hologic, Inc. (HOLX) recently launched new FDA approved Genius Digital Diagnostics System with the Genius Cervical AI algorithm. The launch marks the first and only FDA-cleared digital cytology system that combines deep-learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells.According to American Cancer Society's most current projection, 4,360 women would lose their lives to invasive cervical cancer in the Unite ...